PMID- 32724829
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20220415
IS  - 2314-7156 (Electronic)
IS  - 2314-8861 (Print)
IS  - 2314-7156 (Linking)
VI  - 2020
DP  - 2020
TI  - Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe 
      Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.
PG  - 4975628
LID - 10.1155/2020/4975628 [doi]
LID - 4975628
AB  - BACKGROUND: To investigate the efficacy and safety of guselkumab in the treatment 
      of moderate-to-severe plaque psoriasis. METHODS: A systematic review was 
      undertaken to identify double-blind randomized controlled trials (RCTs). PubMed, 
      Web of Science, Cochrane Library, EMBASE, and Google Scholar databases were 
      searched before 1 March 2020. The odds ratios (ORs) with 95% confidence interval 
      (CI) were calculated. All analyses were conducted with intention-to-treat basis. 
      A range of sensitivity analyses was undertaken. RESULTS: A total of 7 articles 
      contained 1206 plaque psoriasis patients with guselkumab, 585 patients with 
      placebo, and 1250 patients with adalimumab were included. The results indicated 
      that guselkumab had better efficacy than placebo or adalimumab for Psoriasis Area 
      and Severity Index score reductions from baseline of 75% (PASI 75) (OR = 61.37, 
      95% CI = 31.15 to 120.91; OR = 3.08, 95% CI = 2.35 to 4.06), Investigator's 
      Global Assessment scores of 0 or 1 (IGA 0/1) (OR = 65.75, 95% CI = 45.54 to 
      94.95; OR = 2.79, 95% CI = 2.17 to 3.59), and Dermatology Life Quality Index 
      scores of 0 or 1 (DLQI 0/1) (OR = 29.64, 95% CI = 18.80 to 46.73; OR = 1.86, 95% 
      CI = 1.50 to 2.31). The guselkumab had similar safety with placebo or adalimumab 
      about the incidence of adverse events (AEs) (OR = 1.05, 95% CI = 0.86 to 1.29; OR 
      = 0.97, 95% CI = 0.79 to 1.19) and serious adverse events (SAEs) (OR = 1.03, 95% 
      CI = 0.47 to 2.27; OR = 0.91, 95% CI = 0.44 to 1.87). Meanwhile, there was no 
      statistically significant association of infections and serious infections 
      compared with the placebo or adalimumab group. The guselkumab was more effective 
      and had the similar tolerance. CONCLUSION: The guselkumab had excellent efficacy 
      and great safety in moderate-to-severe plaque psoriasis, but long-term safety 
      remained to be determined.
CI  - Copyright (c) 2020 Jing Yang et al.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Dermatology and Venereology, Chong Qing Three Gorges Central 
      Hospital, Chongqing 404100, China.
FAU - Wang, Zongming
AU  - Wang Z
AUID- ORCID: 0000-0002-2885-1400
AD  - Department of Dermatology and Venereology, Chong Qing Three Gorges Central 
      Hospital, Chongqing 404100, China.
FAU - Zhang, Xilin
AU  - Zhang X
AD  - Department of Dermatology and Venereology, Chong Qing Three Gorges Central 
      Hospital, Chongqing 404100, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200717
PL  - Egypt
TA  - J Immunol Res
JT  - Journal of immunology research
JID - 101627166
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 089658A12D (guselkumab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Psoriasis/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Severity of Illness Index
PMC - PMC7382754
COIS- All authors declare no conflicts of interest.
EDAT- 2020/07/30 06:00
MHDA- 2021/06/05 06:00
PMCR- 2020/07/17
CRDT- 2020/07/30 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/07/30 06:00 [entrez]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
PHST- 2020/07/17 00:00 [pmc-release]
AID - 10.1155/2020/4975628 [doi]
PST - epublish
SO  - J Immunol Res. 2020 Jul 17;2020:4975628. doi: 10.1155/2020/4975628. eCollection 
      2020.